Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06892704 · ClinicalTrials.gov registry record
Olfactory Cleft Obstruction and Electrophysiological Field Potentials Predict Olfactory Restoration by Dupilumab in CRSwNP Patients.
A clinical trial of Smell Loss and Chronic Rhinosinusitis Phenotype With Nasal Polyps (CRSwNP), sponsored by Northwestern University.
- Recruiting
- Registry status
- 30
- Enrollment target
- 1
- Study location
NCT06892704: Recruiting study of Smell Loss and Chronic Rhinosinusitis Phenotype With Nasal Polyps (CRSwNP), sponsored by Northwestern University.
NCT06892704 is a study of Smell Loss and Chronic Rhinosinusitis Phenotype With Nasal Polyps (CRSwNP) that is actively recruiting participants, run by Northwestern University. The registered enrollment target is 30 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06892704, a study of Smell Loss and Chronic Rhinosinusitis Phenotype With Nasal Polyps (CRSwNP), is actively recruiting participants, sponsored by Northwestern University.
- RECRUITING
- Registry status
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this observational study is to learn what can predict the return of the sense of smell in patients with chronic rhinosinusitis with nasal polyps being treated with dupilumab. The main questions it aims to answer are: 1. Does obstruction of the olfactory cleft predict return of the sense of smell? 2. Do electrophysiological signals generated by breathing and sniffing behavior predict return of the sense of smell? Participants starting dupilumab will undergo assessment for their degree of olfactory cleft obstruction, and an electrophysiologic assessment of their olfactory cleft and be followed over 6 months of treatment with dupilumab.
Primary Outcome
The brief smell identification test will be administered and patients classified into normal/age-related deficit vs abnormal.
Conditions Studied
Interventions
- DRUG Dupilumab - Standard Dose
Study Locations (1)
Illinois
- Northwestern University Feinberg School of Medicine - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2025-05-01 |
| Est. Completion | 2027-12-31 |
What NCT06892704 shows while recruiting
NCT06892704 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 30 participants, a relatively small participant target.
The record links to 2 conditions, with Smell Loss appearing as the primary indexed condition, and to 1 intervention - of which Dupilumab - Standard Dose is the first listed.
NCT06892704 reports a single indexed study location in Illinois.
Frequently Asked Questions
What is clinical trial NCT06892704 about?
NCT06892704 is a clinical study titled "Olfactory Cleft Obstruction and Electrophysiological Field Potentials Predict Olfactory Restoration by Dupilumab in CRSwNP Patients.". The goal of this observational study is to learn what can predict the return of the sense of smell in patients with chronic rhinosinusitis with nasal polyps being treated with dupilumab. The main questions it aims to answer are: 1. Does obstruction of the olfactory cleft predict return of the sense...
What is the current status of trial NCT06892704?
This trial is currently recruiting. The enrollment target is 30 participants. The study started on 2025-05-01. Estimated completion is 2027-12-31.
What conditions does trial NCT06892704 study?
This clinical trial studies the following conditions: Smell Loss, Chronic Rhinosinusitis Phenotype With Nasal Polyps (CRSwNP).
What interventions are being tested in trial NCT06892704?
The interventions under investigation include: Dupilumab - Standard Dose (DRUG).
Who is sponsoring clinical trial NCT06892704?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06892704 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Smell Loss
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI